Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + orelabrutinib-based first-line therapy for primary CNS large B-cell lymphoma
ChiCTR2100049483Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of orelabrutinib in Diffuse Large B-Cell Primary Central Nervous System Lymphoma (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: 1-year progression-free survival. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
orelabrutinib
03
Conditions
Diffuse Large B-Cell Primary Central Nervous System Lymphoma
Beyond the preview
Go deeper on ChiCTR2100049483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049483.